Problemy ostrogo infarkta miokarda u bol'nykh sakharnym diabetom: ekho Myunkhena
https://doi.org/10.14341/2072-0351-5936
Abstract
Вопрос о сахароснижающей терапии в остром периоде инфаркта миокарда не исчерпан. Доказательством этого является активный интерес ведущих клиник мира к применению в этот период пероральных сахароснижающих препаратов сульфанилмочевины. Пока выбор наиболее адекватного препарата этой группы для применения в остром периоде инфаркта миокарда еще не сделан, но результаты ?Мюнхена? позволяют уже сейчас широко использовать их в практике лечения больных сахарным диабетом в острый период инфаркта миокарда.
About the Authors
Ivan Ivanovich Dedov
Endocrinology Research Centre, Moscow
Russian Federation
Russian Federation
Andrey Alexeevich Aleksandrov
Endocrinology Research Centre, Moscow
Russian Federation
Russian Federation
References
1. Ryden L et al. Guideline on diabetes, pre-diabetes, and cardiovascular diseases,executive summary. Europ Heart J 2007; 28: 88-136.
2. Александров А.А., Оганов Р.Г., Бунаева В.Е., Виноградова И.В. Воздействие на метаболизм сердца у больных острым инфарктом миокарда. Кардиология. 1977; 4: 22-29.
3. Bartnik M, Ryden L, Ferrari R et al. Euro Heart Survei Investigstors. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur Heart J 2004; 25: 1880-1890.
4. Bartnik M. Studies on prevalence recognition and prognostic implication. Glucose regulation and coronary artery disease. Karolinska Institutet, Stockholm 2005 (ISBN: 91-7140-401-5).
5. Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988; 9: 256-264.
6. Karlson BW, Herlitz J, Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients. Diabet Med 1993; 10 (5): 449-454.
7. Rytter L, Beck-Nielsen H, Troelsen S. Diabetic patients and myocardial infarction. Acta Endocrinologica 1984; suppl. 262: 83-87.
8. Herlitz J, Malmberg K, Karlsson B et al. Mortality and morbidity during a five year follow-up of diabetics with myocardial infarction. Acta Med Scand 1988; 24: 31-38.
9. Ulvenstam G, Aberg A, Bergstrang R et al. Long-term prognosis after myocardial infarction in men with diabetes mellitus. Diabetes 1985; 34: 787-792.
10. Orlander PR, Goff DC, Morrissey M et al. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americfns and non-Hispanic whites. The Corpus Christi heart project. Diabetes 1994; 43 (7): 897-902.
11. Jaffe A, Spadaro J, Schehtmann K et al. Increased congestive heart failure myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984; 108: 31-37.
12. Abbud Z, Shindler D, Wilson A, Kostis J. Effect of diabetes mellitus on short and long term mortality rates of patients with acute myocardial infarction: a statewide study . Am Heart J 1995; 130: 51-58.
13. Smith J, Marcus F, Serokman R. Prognosis of patients with diabetes mellitus after myocardial infarction. Am J Cardiol 1984; 54: 718-721.
14. Granger CB, Callif RM, Young S et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The thrombolysis and angioplasty in myocardial infarction (TAMI) study group. J Am Coll Cardiol 1993; 21 (4): 920-925.
15. Singer D, Moulton A, Nathan D. Diabetic myocardial infarction. Interaction of diabetes with other preinfarction risk factors. Diabetes 1989; 38: 350-357.
16. Stone P, Muller J, Hartwell T et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. JACC 1989; 14; 49-57.
17. Savage M, Krolevski A, Kenien G et al. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol 1988; 62: 665-9.
18. Jacoby R, Nesto R. Acute myocardial infarction in the diabetic patients: pathophysiology, clinical course and prognosis. J Am Coll Cardiol 1992; 20: 736-44.
19. Malgorzata Bartnik, Lars Ryden, Roberto Ferrari, Klas Malmberg, Kalevi Pyoraa, Maarten Simoons, Eberhard Standl, Jordi Soler-Soler, and John Ohrvik on behalf of the Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004 25: 1880-1890.
20. Klas Malmberg, Anna Norhammar, Hans Wedel, and Lars Ryd n. Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction : Long-Term Results From the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 1999 99: 2626 - 2632
21. Rogers W, Segal P, McDaniel H, Mantel J, Russet R, Rackley C. Prospective randomised trial of glucose-insulin-potassium in acute myocardial infarction. Am J Cardiol 1979;43:801-808.
22. K. Malmberg, L. Ryd n, H. Wedel, K. Birkeland, A. Bootsma, K. Dickstein, S. Efendic, M. Fisher, A. Hamsten, J. Herlitz, P. Hildebrandt, K. MacLeod, M. Laakso, C. Torp-Pedersen, and A. Waldenstr m for the DIGAMI 2 Investigator Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005 26: 650-661.
23. Brady PA, Al-Suwaidi J, Kopekcy SL, Terzic A. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Circulation 1998; 97: 709-710.
24. Halkin A, Roth A, Jonas B, Behar S. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2001; 12: 177-184.
25. Klamann A, Sarfert P, Launhardt V et al. Myocardial infarction in diabetic and non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibencklamide). Eur Heart J 2000; 21: 220-229.
26. Aronow WS, Ahn C. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol 2001; 88: 556-557.
27. Jollis JG, Simpson RJJr, Cascio WE et al. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999; 138 (5 Pt 1): S376-380.
28. Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metab Clinic Experiment J 2006; 55 (Suppl. 1): S16-S19.
29. Nicolas Danchin et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nation wide French registry. Diabetes Metab Res Rev 2005; 21: 143-149.
30. Gustafsson I et al. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. Europe Heart J 2000; 21: 1937-1943.
Review
For citations:
Dedov I.I., Aleksandrov A.A. Problemy ostrogo infarkta miokarda u bol'nykh sakharnym diabetom: ekho Myunkhena. Diabetes mellitus. 2008;11(1):4-10. (In Russ.) https://doi.org/10.14341/2072-0351-5936
Views:
7089
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
